Jonathan O'Brien (Cork North Central, Sinn Fein)
Link to this: Individually | In context | Oireachtas source

719. To ask the Minister for Health his plans to include the i-port Advance injection device on the long-term illness scheme for the treatment of persons with type 1 diabetes; and the reason this has not happened before now. [20582/15]

Fergus O'Dowd (Louth, Fine Gael)
Link to this: Individually | In context | Oireachtas source

720. To ask the Minister for Health if he will ensure that the Health Service Executive will make Medtronic’s i-port Advance injection device available for diabetic children, as proposed by a person (details supplied); and if he will make a statement on the matter. [20583/15]

Micheál Martin (Cork South Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

721. To ask the Minister for Health if consideration is being given to making a product (details supplied) available under the long-term illness scheme. [20595/15]

Terence Flanagan (Dublin North East, Independent)
Link to this: Individually | In context | Oireachtas source

730. To ask the Minister for Health if a product will be made available for children with diabetes (details supplied); and if he will make a statement on the matter. [20667/15]

Clare Daly (Dublin North, United Left)
Link to this: Individually | In context | Oireachtas source

736. To ask the Minister for Health the reason Medtronic’s i-port Advance injection device is not included on the long-term illness scheme. [20713/15]

Michael Healy-Rae (Kerry South, Independent)
Link to this: Individually | In context | Oireachtas source

742. To ask the Minister for Health his views on the pricing of a medical device (details supplied) in view of its importance to young persons with diabetes; and if he will make a statement on the matter. [20723/15]

Finian McGrath (Dublin North Central, Independent)
Link to this: Individually | In context | Oireachtas source

757. To ask the Minister for Health the position regarding provision of a medical device (details supplied) for young persons with diabetes; and if he will make a statement on the matter. [20813/15]

Kathleen Lynch (Cork North Central, Labour)
Link to this: Individually | In context | Oireachtas source

I propose to take Questions Nos. 719 to 721, inclusive, 730, 736, 742 and 757 together.

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicinal products under the community drug schemes in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013.

The decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds by the HSE on the advice of the National Centre for Pharmacoeconomics. They are not political or ministerial decisions.

The HSE received an application for the inclusion of the product, i-port Advance™, to be added to the List of Reimbursable Items in the GMS and community drugs schemes. The application was considered in line with the procedures and timescales agreed by the Department of Health and the HSE with the Irish Pharmaceutical Healthcare Association for the assessment of new medicines.

An Expert Group, chaired by the Clinical Lead of the HSE Diabetes Programme, was convened by the HSE to (i) assess the clinical evidence to support the use of the product, (ii) consider whether the product is appropriate for reimbursement status under Schemes and (iii) assist in the determination of the ‘value’ that the innovation presents. The Expert Group did not find that the product was either clinically effective or cost effective, and therefore did not recommend that the product should be reimbursed. The Director of Primary Care accepted the recommendation of the Expert Group and the company was informed of the HSE's decision on the 20 April 2015.